UNSPSC 51393701: Oxitropium

This classification denotes an antimuscarinic agent with the molecular structure C19H26NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8G15T83E6I chemically known as (7(s)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.))-9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane but generally known as oxitropium, which bears US NIH Compound Identifier 5311335. European Medicines Agency schedules Oxitropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03574MIG.

As of Q4 2014, OXITROPIUM remains the US FDA Preferred Term for this commodity. Oxitropium bears US NLM identifiers UMLS ID C0069776 and NCI Concept Code C87641. SMILES: BR.O1C2C3[N](C(C12)CC(OC(=O)C(CO)C1CCCCC1)C3)(CC)C.

UNSPSC 51393701 Oxitropium is a Commodity code that does not align with the state and local opportunities recently posted under this classification. The Seminole County, Florida IFB procurement (IFB60459723LAS, due Jul 26, 2023) solicits naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013, due Apr 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription fulfillment programs. Neither opportunity matches the scope of oxitropium, which is a specific pharmaceutical compound used in respiratory therapy. The code shows minimal relevant recent activity aligned with its nominal scope.

The mismatch between the code classification and actual procurement work signals either a tagging error in the source data or a code that sees limited state and local demand. Firms evaluating this Commodity code should verify their product and service alignment directly with issuing bodies rather than rely on the code's nominal definition as a predictor of opportunity volume or type.